Somu Subramaniam - Sep 18, 2023 Form 4 Insider Report for Ventyx Biosciences, Inc. (VTYX)

Role
Director, 10%+ Owner
Signature
/s/ Christopher Krueger, as Attorney-in-Fact
Stock symbol
VTYX
Transactions as of
Sep 18, 2023
Transactions value $
-$2,142,634
Form type
4
Date filed
9/20/2023, 07:19 PM
Previous filing
Aug 1, 2023
Next filing
Oct 11, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction VTYX Common Stock Sale -$2.14M -56.7K -0.66% $37.81 8.49M Sep 18, 2023 See Footnotes F1, F2, F3, F4, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by NSV Partners III, L.P. on February 24, 2023.
F2 Represents the weighted average share price of an aggregate total of 56,665 shares sold in the price range of $37.50 to $38.115. The reporting owner undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
F3 NSV Partners III, L.P. is the general partner of NSV Investments I, L.P., NSV Investments III, L.P., and NSV Investments II, L.P.
F4 The reporting person is the majority member and managing member of NSV Partners III GP, LLC, and may be deemed to have voting and dispositive power over the shares owned by each entity of which NSV Partners III, L.P. is general partner. The reporting person is the majority member and managing member NSV Partners II, LLC. The reporting person is the majority member and managing member of New Science Ventures, LLC. The reporting person disclaims beneficial ownership over the shares owned by each of the NSV Funds (as defined below), except to the extent of his pecuniary interest therein.
F5 The shares beneficially owned by the reporting persons consist of: (i) 5,004,071 shares owned by NSV Investments I, L.P., (ii) 978,835 shares owned by NSV Investments III, L.P., (iii) 1,430,758 shares owned by NSV Partners III, L.P., (iv) 434,423 shares owned by New Science Ventures, LLC, (v) 408,520 shares owned by NSV Partners II, LLC, and (vi) 232,180 shares owned by NSV Investments II, L.P (collectively, the "NSV Funds"). The NSV Funds disclaim beneficial ownership over the shares owned by them, except to the extent of their pecuniary interest therein.